Lower Price For Tecentriq In ES-SCLC Secures Coverage In England
Executive Summary
Hot on the heels of recommending Roche’s drug for triple negative breast cancer, HTA body NICE today said the product should also be used for the first-line treatment of extensive-stage small-cell lung cancer.